Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 8 entries
To evaluate the usefulness, safety, and effectiveness of intravenous ExoFlo in patients with Crohn’s disease who are not responding to conventional therapies.
To evaluate the usefulness, safety, and effectiveness of intravenous ExoFlo in patients with ulcerative colitis who are not responding to conventional therapies.
To evaluate the safety and effectiveness of ExoFlo in patients with perianal fistula(s) due to Crohn’s disease.
Primary Objective: Safety and Tolerability
Secondary Objective: Efficacy
Understand how diet influences inflammation, symptoms, and the biology of Crohn's disease
This is a clinical trial with healthy participants to:
• see how the study drug is tolerated, if there are significant side effects, and how people feel after taking it when given with a single dose of another medication (drug B)
• see if multiple doses of the study drug have an effect on the amount of drug B in your blood after a single dose
• measure how much of drug B is in your blood after you take a single dose
This is a clinical trial with healthy participants to:
• measure how a single oral dose of the study drug affects the body and certain types of blood cells and enzymes
• measure the amount of study drug in your blood 48 hours after a single dose
• see how a new drug under study is tolerated, if there are any significant side effects and how people feel after taking it
The study objectives are to: 1) assess the safety of oral administration of EcoActive (twice daily, for 15 days) in patients with clinically inactive Crohn’s disease having Adherent Invasive Escherichia coli (AIEC) present in their stools; and, 2) evaluate changes in AIEC incidence and levels in stools of patients receiving treatment versus placebo-treated controls.
The Featured Study Opportunities page is made possible in part by:
